Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

development of SGX523.

SGX126: The Company is continuing development of SGX126. While SGX126 shares many of the attractive preclinical properties of SGX523, it is structurally distinct, more potent in vivo and, based on the results of preclinical studies, has a different metabolism profile than that of SGX523. The Company intends to carry out further preclinical studies on SGX126 in support of clinical development and an IND submission is now targeted for early 2009.

Additional MET Inhibitors: In addition to SGX126, the Company has a number of MET inhibitors with attractive potency, selectivity and pharmacokinetic properties that it is evaluating as further MET development candidates.

BCR-ABL Program

SGX393: The Company's internal BCR-ABL program, focused on relapsed and refractory CML patients, in particular those with the T315I mutation, is progressing through IND-enabling studies, with an IND submission targeted for this quarter. Novartis continues to be responsible for the further preclinical and clinical development of BCR-ABL inhibitors identified under the collaboration, other than SGX393.

Oncology Drug Discovery

In addition to the JAK2 and RAS programs described previously, the Company's drug discovery portfolio includes other exciting cancer targets, such as RON, ALK, and IKKe. The JAK2, RON, and ALK programs are the more advanced drug discovery programs and the Company is targeting nomination of at least two development candidates from its drug discovery portfolio later this year.

Financial Results for the Three Months Ended March 31, 2008

Total revenues in the first quarter of 2008 were $17.0 million compared to $11.0 million in the first quarter of 2007. The increase of $6.0 million is primarily due to an increase in revenue recognized under the Novartis collaboration. Specifically, upon the conclusion of the research term of the collaboration in late March 2008, the Company recognized as revenue ap
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Editors note: This is the first of a series of columns ... and advice on IT leadership and the challenges they face. ... 95 percent of his customers want more of what he has ... ready to meet that demand. , ,David Wallace is the CIO ...
... arteries. Source: National Institutes of Health. Madison, Wis. ... researcher, announced on Wednesday that it will receive a $1.26 ... National Institutes of Health. , ,The funds will be used ... anemia, a blood disorder that kills red blood cells. This ...
... getting a flu shot this season and you want to fix ... mirror. If the face you see belongs to someone who buys ... the problem. , ,The looming shortage of flu vaccine comes down ... in the business of making vaccines. Why? The capital costs are ...
Cached Biology Technology:MATC faces demand for less paper and more integration 2MATC faces demand for less paper and more integration 3Mirus receives $1.26 million SBIR grant to combat anemia 2Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for 2Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for 3
(Date:7/9/2014)... of the amphibians with the highest distribution in the ... water where it comes into contact with the red ... out by the Spaniard Germn Orizaola from the University ... frogs have developed a defensive response to the invasive ... if they co-exist with the crayfish. , Numerous invasive ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
(Date:7/9/2014)... inhibitors and N-methyl-D-aspartate receptor antagonists can alleviate ... to affect irreversible cognitive dysfunction and effectively ... Amyloid beta peptide (Aβ) vaccines reduced and ... (AD) transgenic mouse model, and significantly improved ... and his team, First Affiliated Hospital of ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3Managing the data jungle 2Managing the data jungle 3
... researchers have sequenced the genomes of two bacteria that ... Brazil and elsewhere. , The researchers are now analysing ... that could be used to develop vaccines and diagnostic ... in pigs and costs the Brazilian pig-breeding industry US$200 ...
... once were bountiful in an area near the town of ... grew more plentiful, browsing heavily on young willows. Today, there ... warblers in what is now a grassland meadow. These profound ... top predator. That's the compelling finding of the paper, "Human ...
... of boosting the yield of a major crop by stopping ... is the most important oilseed crop in India after groundnut. ... seeds. However, because the seedpods open naturally to disperse their ... , This 'pod shatter' also makes it difficult for farmers ...
Cached Biology News:Wolves' top-down effect 2
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: